Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection

Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a new class of antiretroviral drugs. Raltegravir has been studied extensively in clinical trials, and has been well tolerated and highly effective in both treatment-naïve and -experienced patients. Resistance to...

Full description

Saved in:
Bibliographic Details
Published in:Infection and drug resistance 2010, Vol.3 (default), p.15-23
Main Authors: Chirch, Lisa M, Steigbigel, Roy T
Format: Article
Language:English
Subjects:
Antiretroviral agents
Antiretroviral drugs
Clinical trials
HIV
Human immunodeficiency virus
Integrase
Patients
Review
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a new class of antiretroviral drugs. Raltegravir has been studied extensively in clinical trials, and has been well tolerated and highly effective in both treatment-naïve and -experienced patients. Resistance to raltegravir is unusual given its recent availability, but resistance with identified viral mutation pathways in the integrase gene in patients receiving the drug does occur.
ISSN:1178-6973
1178-6973
DOI:10.2147/idr.s9689